Skip to main content
PAHC
NASDAQ Life Sciences

Phibro Animal Health Reports Surging Q2 Profits, Raises Full-Year Guidance

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Pharmaceutical Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$45.38
Mkt Cap
$1.662B
52W Low
$16.16
52W High
$46.42
52W Position info
181% above low
Off High info
2.2% below high
Rel. Volume info
1.2× avg
Market data snapshot near publication time

PAHC has more than doubled off its 52-week low of $16.16.

Summary

Phibro Animal Health announced outstanding Q2 FY2026 results, with net income up over 700% and adjusted EBITDA up 41%, leading to a significant raise in full-year guidance.


Key Events · Earnings and Guidance · PAHC

  • Exceptional Q2 FY2026 Financial Performance

    Net sales increased 21% to $373.9 million, and net income surged over 700% to $27.5 million for the quarter ended December 31, 2025.

  • Strong Profitability Growth

    Adjusted EBITDA rose 41% to $68.1 million, and adjusted diluted EPS increased 58% to $0.87, demonstrating robust operational efficiency.

  • Raised Full-Year Guidance

    The company significantly increased its fiscal year 2026 guidance, now projecting net sales of $1.45 billion to $1.50 billion and adjusted EBITDA of $245 million to $255 million.

  • Successful Strategic Execution

    CEO Jack Bendheim highlighted faster-than-expected uptake of the newly integrated MFA portfolio and sustained growth in nutritional specialty and vaccine offerings as key drivers.


Analysis · PAHC · Life Sciences

Phibro Animal Health Corporation reported exceptionally strong financial results for the second quarter of fiscal year 2026, with net income surging over 700% year-over-year and adjusted EBITDA increasing by 41%. This robust performance, driven by successful integration of its MFA portfolio and sustained growth in other segments, led the company to significantly raise its full-year fiscal 2026 guidance for both net sales and adjusted EBITDA. This positive announcement, made via press release furnished in this 8-K and detailed in the concurrently filed 10-Q, reinforces investor confidence, especially as the stock is trading near its 52-week high.

At the time of this filing, PAHC was trading at $45.38 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.7B. The 52-week trading range was $16.16 to $46.42. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

PAHC - Latest Insights

PAHC
Jun 26, 2026, 5:07 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $31.69
Real-time Price: $34.04 info
Change: +$2.34 (+7%) info
Market Cap: $1.381B info
PAHC
May 22, 2026, 4:24 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
8
Price at Filing: $33.26
Real-time Price: $34.04 info
Change: +$0.775 (+2%) info
Market Cap: $1.381B info
PAHC
May 06, 2026, 4:44 PM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $58.50
Real-time Price: $34.04 info
Change: -$24.47 (-42%) info
Market Cap: $1.381B info
PAHC
May 06, 2026, 4:39 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $55.08
Real-time Price: $34.04 info
Change: -$21.05 (-38%) info
Market Cap: $1.381B info
PAHC
May 06, 2026, 4:25 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $57.00
Real-time Price: $34.04 info
Change: -$22.97 (-40%) info
Market Cap: $1.381B info